By Karen Deyo, Director of Investor Research, Israel BD, LSN
The Redefining Early Stage Investments (RESI) conference series has been a stop along the way for global investors seeking to build a robust portfolio of companies innovating drugs, devices, diagnostics, and digital health. As the conference has grown in attendance, frequency, and popularity, as well as developed two accompanying conferences (RESI AI and RESI Longevity), the opportunities for investors have also expanded through the RESI Investor Program. The RESI Investor Program includes several opportunities for investors to make the most of their experience with RESI and source under-the-radar, hard-to-find technologies that are a fit for their mandate, advance deals, or even help their current portfolio companies expand.
Through the program, investors can tailor their experience and capitalize on Life Science Nation (LSN)’s vast database of early-stage fundraising companies in a diverse set of sectors, indications, and applications. It combines the ease of the RESI platform with the expertise of the team behind the scenes. Schedule a meeting with the investor research team and LSN CEO, Dennis Ford to share your unique sourcing needs and learn how LSN can help you build relationships with the companies that are a fit for you. View the brochure and get the conversation started.
 |
 |
Next Phase Newsletter 
Leave a Reply